A qualitative study of key stakeholders' perceived risks and benefits of psychiatric electroceutical interventions

Amid a renewed interest in alternatives to psychotherapy and medication to treat depression, there is limited data as to how different stakeholders perceive of the risks and benefits of psychiatric electroceutical interventions (PEIs), including electroconvulsive therapy (ECT) and deep brain stimulation (DBS). To address this gap, we conducted 48 semi-structured interviews, including 16 psychiatrists, 16 persons diagnosed with depression, and 16 members of the general public. To provide a basis of comparison, we asked participants to also compare each modality to front-line therapies for depression and to neurosurgical procedures used for non-psychiatric conditions. Across all stakeholder groups, perceived memory loss was the most frequently mentioned potential risk with ECT. The most discussed benefits across all stakeholder groups were efficacy and quick response. Psychiatrists most often referenced effectiveness when discussing ECT, while patients and the public did so when discussing DBS. Taken as a whole, these data highlight stakeholders’ contrasting perspectives on the risks and benefits of electroceuticals.

This is an Accepted Manuscript of an article published by Taylor & Francis in Health, Risk & Society on 2021-08-18, available online: https://www.tandfonline.com/10.1080/13698575.2021.1979194.

Files

Metadata

Work Title A qualitative study of key stakeholders' perceived risks and benefits of psychiatric electroceutical interventions
Access
Open Access
Creators
  1. Laura Y. Cabrera
  2. Gerald R. Nowak
  3. Aaron M. McCright
  4. Eric Achtyes
  5. Robyn Bluhm
Keyword
  1. electroceuticals
  2. patients
  3. perceived benefits
  4. perceived risks
  5. psychiatrists
  6. public understanding
License CC BY-NC 4.0 (Attribution-NonCommercial)
Work Type Article
Publisher
  1. Informa UK Limited
Publication Date August 18, 2021
Publisher Identifier (DOI)
  1. 10.1080/13698575.2021.1979194
Source
  1. Health, Risk & Society
Deposited May 27, 2022

Versions

Analytics

Collections

This resource is currently not in any collection.

Work History

Version 1
published

  • Created
  • Added Risks-and-Benefits-paper-HRS_Final-revisions with affiliations-1.docx
  • Added Creator Laura Y. Cabrera
  • Added Creator Gerald R. Nowak
  • Added Creator Aaron M. McCright
  • Added Creator Eric Achtyes
  • Added Creator Robyn Bluhm
  • Published
  • Updated Work Title, Keyword, Description Show Changes
    Work Title
    • A qualitative study of key stakeholders perceived risks and benefits of psychiatric electroceutical interventions
    • ! A qualitative study of key stakeholders' perceived risks and benefits of psychiatric electroceutical interventions
    Keyword
    • electroceuticals, patients, perceived benefits, perceived risks, psychiatrists , public understanding
    Description
    • <p>Amid a renewed interest in alternatives to psychotherapy and medication to treat depression, there is limited data as to how different stakeholders perceive of the risks and benefits of psychiatric electroceutical interventions (PEIs), including electroconvulsive therapy (ECT) and deep brain stimulation (DBS). To address this gap, we conducted 48 semi-structured interviews, including 16 psychiatrists, 16 persons diagnosed with depression, and 16 members of the general public. To provide a basis of comparison, we asked participants to also compare each modality to front-line therapies for depression and to neurosurgical procedures used for non-psychiatric conditions. Across all stakeholder groups, perceived memory loss was the most frequently mentioned potential risk with ECT. The most discussed benefits across all stakeholder groups were efficacy and quick response. Psychiatrists most often referenced effectiveness when discussing ECT, while patients and the public did so when discussing DBS. Taken as a whole, these data highlight stakeholders’ contrasting perspectives on the risks and benefits of electroceuticals.</p>
    • Amid a renewed interest in alternatives to psychotherapy and medication to treat depression, there is limited data as to how different stakeholders perceive of the risks and benefits of psychiatric electroceutical interventions (PEIs), including electroconvulsive therapy (ECT) and deep brain stimulation (DBS). To address this gap, we conducted 48 semi-structured interviews, including 16 psychiatrists, 16 persons diagnosed with depression, and 16 members of the general public. To provide a basis of comparison, we asked participants to also compare each modality to front-line therapies for depression and to neurosurgical procedures used for non-psychiatric conditions. Across all stakeholder groups, perceived memory loss was the most frequently mentioned potential risk with ECT. The most discussed benefits across all stakeholder groups were efficacy and quick response. Psychiatrists most often referenced effectiveness when discussing ECT, while patients and the public did so when discussing DBS. Taken as a whole, these data highlight stakeholders’ contrasting perspectives on the risks and benefits of electroceuticals.
  • Updated Work Title Show Changes
    Work Title
    • ! A qualitative study of key stakeholders' perceived risks and benefits of psychiatric electroceutical interventions
    • A qualitative study of key stakeholders' perceived risks and benefits of psychiatric electroceutical interventions
  • Updated